U.S. Preventive Services 

Task Force banner
U.S. Preventive Services Task Force

Risk Factors and Other Epidemiologic Considerations for Cervical Cancer Screening (continued)


1. SEER Cancer Statistics Review, 1975-2009. Bethesda, MD: National Cancer Institute; 2011. Accessed at http://seer.cancer.gov/csr/1975_2008/results_merged/sect_05_cervix_uteri.pdf on 21 Apr 2011.

2. Surveillance Epidemiology and End Results (SEER). SEER*Stat Database: All COD, Aggregated with State, Total U.S. (1969-2007). Bethesda, MD: National Cancer Institute; 2011.

3. Sung HY, Kearney KA, Miller M, Kinney W, Sawaya GF, Hiatt RA. Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer. 2000;88:2283-9. [PMID: 10820350]

4. Kinney W, Sung HY, Kearney KA, Miller M, Sawaya G, Hiatt RA. Missed opportunities for cervical cancer screening of HMO members developing invasive cervical cancer (ICC). Gynecol Oncol. 1998;71:428-30. [PMID: 9887244]

5. Leyden WA, Manos MM, Geiger AM, Weinmann S, Mouchawar J, Bischoff K, et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst. 2005;97:675-83. [PMID: 15870438]

6. Janerich DT, Hadjimichael O, Schwartz PE, Lowell DM, Meigs JW, Merino MJ, et al. The screening histories of women with invasive cervical cancer, Connecticut. Am J Public Health. 1995;85:791-4. [PMID: 7762711]

7. International Agency for Research on Cancer. IARC Handbooks of Cancer Prevention: Cervix Cancer Screening. Lyon, France: IARC Pr; 2005.

8 .Vesco KK, Whitlock EP, Eder M, Lin J, Burda BU, Senger CA, et al. Screening for Cervical Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 86. AHRQ Publication No. 11-05156-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2011.

9. Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, Burda BU. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;Oct 18. [Epub ahead of print]

10.. U.S. Preventive Services Task Force. USPSTF Procedure Manual. AHRQ Publication No. 08-05118-EF. Rockville, MD, Agency for Healthcare Research and Quality; 2008.

11. Kulasingam S, Havrilesky L, Ghebre R, Myers ER. Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. AHRQ Publication No. 11-05157-EF-1. Rockville, MD: Agency for Heatlhcare Research and Quality; 2011.

12. American Cancer Society. Cervical cancer. Atlanta: American Cancer Society; 2006. Accessed at www.cancer.org/cancer/cervicalcancer/index on 19 Apr 2011.

13. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al; Forum Group Members. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114-9. [PMID: 11966386]

14. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890-907. [PMID: 17826171]

15. Cox JT, Schiffman M, Solomon D; ASCUS-low-grade squamous intraepithelial lesion Triage Study (ALTS) Group. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol. 2003;188:1406-12. [PMID: 12824970]

16. Dalla Palma P, Giorgi Rossi P, Collina G, Buccoliero AM, Ghiringhello B, Gilioli E, et al; NTCC Pathology Group. The reproducibility of CIN diagnoses among different pathologists: data from histology reviews from a multicenter randomized study. Am J Clin Pathol. 2009;132:125-32. [PMID: 19864243]

17. Carreon JD, Sherman ME, Guillén D, Solomon D, Herrero R, Jerónimo J, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol. 2007;26:441-6. [PMID: 17885496]

18. Ostör AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12:186-92. [PMID: 8463044]

19. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009;113:18-25. [PMID: 19104355]

20. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9:425-34. [PMID: 18407790]

21. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24(Suppl 1):S1-15. [PMID: 16406226]

22. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011;103:368-83. [PMID: 21282563]

23. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003;89:101-5. [PMID: 12838308]

24. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621-32. [PMID: 17405118]

25. Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer. 2004;91:942-53. [PMID: 15292939]

26. Cotton SC, Sharp L, Seth R, Masson LF, Little J, Cruickshank ME, et al; TOMBOLA Group. Lifestyle and socio-demographic factors associated with high-risk HPV infection in UK women. Br J Cancer. 2007;97:133-9. [PMID: 17519896]

27. Datta SD, Koutsky LA, Ratelle S, Unger ER, Shlay J, McClain T, et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med. 2008;148:493-500. [PMID: 18378945]

28. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM; ALTS Group. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007;195:1582-9. [PMID: 17471427]

29. Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives. Cancer Epidemiol Biomarkers Prev. 2007;16:709-15. [PMID: 17416761]

30. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97:1072-9. [PMID: 16030305]

31. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001;357:1831-6. [PMID: 11410191]

32. Cox JT. The development of cervical cancer and its precursors: what is the role of human papillomavirus infection? Curr Opin Obstet Gynecol. 2006;18(Suppl 1):s5-s13. [PMID: 16520683]

33. Berrington de González A, Green J; International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007;120:885-91. [PMID: 17131323]

34. Castellsagué X, Díaz M, de Sanjosé S, Muñoz N, Herrero R, Franceschi S, et al; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006;98:303-15. [PMID: 16507827]

35. Bosch FX, de Sanjosé S. The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers. 2007;23:213-27. [PMID: 17627057]

36. Ault KA. Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol. 2006;2006(Suppl):40470. [PMID: 16967912]

37. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer. 2006;119:1108-24. [PMID: 16570271]

38. Muñoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, et al; International Agency for Research on Cancer. Multicentric Cervical Cancer Study Group. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet. 2002;359:1093-101. [PMID: 11943256]

39. Moreno V, Bosch FX, Muñoz N, Meijer CJ, Shah KV, Walboomers JM, et al; International Agency for Research on Cancer. Multicentric Cervical Cancer Study Group. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet. 2002;359:1085-92. [PMID: 11943255]

40. Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, Goodill A, et al; International Collaboration of Epidemiological Studies of Cervical Cancer. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer. 2006;118:1481-95. [PMID: 16206285]

41. Plummer M, Herrero R, Franceschi S, Meijer CJ, Snijders P, Bosch FX, et al; IARC Multi-centre Cervical Cancer Study Group. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. Cancer Causes Control. 2003;14:805-14. [PMID: 14682438]

42. Kalliala I, Anttila A, Pukkala E, Nieminen P. Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study. BMJ. 2005;331:1183-5. [PMID: 16293840]

43. Strander B, Andersson-Ellström A, Milsom I, Sparén P. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ. 2007;335:1077. [PMID: 17959735]

44. Kalliala I, Dyba T, Nieminen P, Hakulinen T, Anttila A. Mortality in a long-term follow-up after treatment of CIN. Int J Cancer. 2010;126:224-31. [PMID: 19585576]

45. Surveillance Epidemiology and End Results (SEER). SEER*Stat Database: Incidence — SEER 17 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2010 Sub (1973-2008 varying). Bethesda, MD: National Cancer Institute; 2011.

46. Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol. 2004;191:105-13. [PMID: 15295350]

47. Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ. 2009;339:b2968. [PMID: 19638651]

48. Sigurdsson K, Sigvaldason H. Is it rational to start population-based cervical cancer screening at or soon after age 20? Analysis of time trends in preinvasive and invasive diseases. Eur J Cancer. 2007;43:769-74. [PMID: 17236755]

49. ACOG Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin no. 109: Cervical cytology screening. Obstet Gynecol. 2009;114:1409-20. [PMID: 20134296]

50. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D; 2006 ASCCP-Sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis. 2007;11:201-22. [PMID: 17917566]

51. TOMBOLA Group. Cytological surveillance compared with immediate referral for colposcopy in management of women with low grade cervical abnormalities: multicentre randomised controlled trial. BMJ. 2009;339:b2546. [PMID: 19638646]

52. Sharp L, Cotton S, Cochran C, Gray N, Little J, Neal K, et al; TOMBOLA (Trial Of Management of Borderline and Other Low-grade Abnormal smears) Group. After-effects reported by women following colposcopy, cervical biopsies and LLETZ: results from the TOMBOLA trial. BJOG. 2009;116:1506-14. [PMID: 19583712]

53. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006;367:489-98. [PMID: 16473126]

54. Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ. 2008;337:a1284. [PMID: 18801868]

55.. National Health Service Cervical Screening Programme. About cervical cancer screening. Sheffield, UK: National Health Service; 2011. Accessed at www.cancerscreening.nhs.uk/cervical/about-cervical-screening.html on 11 May 2011.

56. HSC Public Health Agency. NI Cancer Screening Programmes. History of the cervical screening programme. Belfast, Ireland: Health and Social Care; 2011. Accessed at http://www.cancerscreening.hscni.net/cervical/02-B-CERVICALHISTORY.html#P-4_0 on 29 July 2011.

57. Cervical Screening Wales. Cardiff: Public Health Wales; 2011. Accessed at www.screeningservices.org.uk/csw/pub/index.asp on 20 September 2011.

58. The Scottish Government. Cervical cancer screening programme. Edinburgh, Scotland: The Scottish Government; 2008. Accessed at www.scotland.gov.uk/Topics/Health/health/cancer/Cancer-Screening/ccscreening on 25 July 2011.

59. Australia Department of Health and Aging. National cervical screening programme. Canberra, Australia: Australia Department of Health and Aging; 2009. Accessed at www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/cervical-about on 11 May 2011.

60. Canadian Task Force on Preventive Health Care. Screening for cervical cancer. Ottawa: Canadian Task Force on Preventive Health Care; 1994. Accessed at www.canadiantaskforce.ca/_archive/index.html on 11 May 2011.

61. Arbyn M, Antilla A, Jordan J, Ronco G, Schenck U, Segnan N, et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. 2nd ed. Luxembourg: European Commission; 2008.

62. Finnish Cancer Registry. Cervical Cancer Screening: Screening Programme. Helsinki: Institute for Statistical and Epidemiological Cancer Research; 2011.

63. Dowling EC, Klabunde C, Patnick J, Ballard-Barbash R; International Cancer Screening Network (ICSN). Breast and cervical cancer screening programme implementation in 16 countries. J Med Screen. 2010;17:139-46. [PMID: 20956724]

64. New Zealand National Cervical Screening Programme. Guidelines for cervical screening in New Zealand. Incorporating the Management of Women with Abnormal Cervical Smears. Wellington, New Zealand: National Screening Unit, Ministry of Health; 2008. Accessed at www.nsu.govt.nz/files/NCSP/NCSP_Guidelines_ALL_small(1).pdf on 11 May 2011.

65. American Cancer Society. American Cancer Society Guidelines for the Early Detection of Cancer. Atlanta: American Cancer Society; 2010. Accessed at www.cancer.org/Healthy/FindCancerEarly/CancerScreeningGuidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer on 11 May 2011

66. American Academy of Family Physicians. Cervical cancer. Leawood, KS: American Academy of Family Physicians; 2008. Accessed at www.aafp.org/online/en/home/clinical/exam/cervicalcancer.html on 11 May 2011.

67. Hawkes AP, Kronenberger CB, MacKenzie TD, Mardis AL, Palen TE, Schulter WW, et al. Cervical cancer screening: American College of Preventive Medicine practice policy statement. Am J Prev Med. 1996;12:342-4. [PMID: 8909644]

68. U.S. Preventive Services Task Force. Screening for Cervical Cancer: Recommendations and Rationale. Rockville, MD: Agency for Healthcare Research and Quality; 2003.

69. Sasieni P, Castanon A. Call and recall cervical screening programme: screening interval and age limits. Curr Diagn Pathol. 2006;12:114-26.

70. Mandelblatt J, Lawrence W, Yi B, King J. The balance of harms, benefits, and costs of screening for cervical cancer in older women: the case for continued screening. Arch Intern Med. 2004;164:245-7; discussion 247-8. [PMID: 14769618]

71. Hartmann KE, Hall SA, Nanda K, Boggess JF, Zolnoun D. Screening for Cervical Cancer. Systematic Review No. 25. Rockville, MD: Agency for Healthcare Research and Quality; 2002.

72. Armaroli P, Gallo F, Bellomi A, Ciatto S, Consonni D, Davi D, et al. Do women ≥ 50 years of age need as much screening as women <50 years after they have had negative screening results? Br J Cancer. 2008;99:239-44. [PMID: 18594534]

73. Rebolj M, van Ballegooijen M, Lynge E, Looman C, Essink-Bot ML, Boer R, et al. Incidence of cervical cancer after several negative smear results by age 50: prospective observational study. BMJ. 2009;338:b1354. [PMID: 19395420]

74. Centers for Disease Control and Prevention. Cervical cancer screening rates. Atlanta: Centers for Disease Control and Prevention; 2011. Accessed at www.cdc.gov/cancer/cervical/statistics/screening.htm on 8 Apr 2011.

75. Fahs MC, Mandelblatt J, Schechter C, Muller C. Cost effectiveness of cervical cancer screening for the elderly. Ann Intern Med. 1992;117:520-7. [PMID: 1503355]

76. Surveillance Epidemiology and End Results (SEER) Program. SEER Stat Fact Sheets: Cervix Uteri. Bethesda, MD: National Cancer Institute; 2010. Accessed at http://seer.cancer.gov/statfacts/html/cervix.html#incidence-mortality on 21 Apr 2011.

77. Henley SJ, King JB, German RR, Richardson LC, Plescia M; Centers for Disease Control and Prevention (CDC). Surveillance of screening-detected cancers (colon and rectum, breast, and cervix) — United States, 2004-2006. MMWR Surveill Summ. 2010;59(9):1-25. [PMID: 21102407]

78. Barnholtz-Sloan J, Patel N, Rollison D, Kortepeter K, MacKinnon J, Giuliano A. Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity. Cancer Causes Control. 2009;20:1129-38. [PMID: 19253025]

79. McDougall JA, Madeleine MM, Daling JR, Li CI. Racial and ethnic disparities in cervical cancer incidence rates in the United States, 1992-2003. Cancer Causes Control. 2007;18:1175-86. [PMID: 17805982]

80. Xu J, Kochanek KD, Murphy SL, Tejada-Vera B. Deaths: final data for 2007. Natl Vital Stat Rep. 2007;58:1-135.

81. Lewis CL, Couper MP, Levin CA, Pignone MP, Zikmund-Fisher BJ. Plans to stop cancer screening tests among adults who recently considered screening. J Gen Intern Med. 2010;25:859-64. [PMID: 20407841]

82. Sawaya GF, Iwaoka-Scott AY, Kim S, Wong ST, Huang AJ, Washington AE, et al. Ending cervical cancer screening: attitudes and beliefs from ethnically diverse older women. Am J Obstet Gynecol. 2009;200:e1-7. [PMID: 18976734]

Return to First Section

Copyright and Source Information

Source: This article was first published in Annals of Internal Medicine (Ann Intern Med 2011 Oct 18. [Epub ahead of print]).

Acknowledgment: The authors thank Rebecca Holmes, MD, MS; Jennifer Lin, MD, MCR; and Sarah Zuber, MSW, for individual and team contributions to the evidence report.

Grant Support: This review was conducted by the Oregon Evidence-based Practice Center under contract to AHRQ, Rockville, Maryland (contract HHS-290-2007-10057-I, task order 3). The AHRQ staff provided oversight for the project and assisted in external review of the companion draft evidence synthesis. The USPSTF liaisons helped to resolve issues around the scope of the evidence synthesis but were not involved in the conduct of the review.

Potential Conflicts of Interest: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M11-1382 Exit Disclaimer.

Current author addresses: Drs. Vesco, Whitlock, and Eder; Ms. Burda; Ms. Senger; and Mr. Lutz: Center for Health Research, Kaiser Permanente Northwest, 3800 North Interstate Avenue, Portland, OR 97227.

AHRQ Publication No. 11-05156-EF-4
Current as of October 2011

Return to First Section

Internet Citation:

Vesco KK, Whitlock EP, Eder M, Burda BU, Senger CA, Lutz K. Risk Factors and Other Epidemiologic Considerations for Cervical Cancer Screening: A Narrative Review. AHRQ Publication No. 11-05156-EF-4. October 2011. http://www.uspreventiveservicestaskforce.org/uspstf11/cervcancer/cervcancerart.htm


USPSTF Program Office   540 Gaither Road, Rockville, MD 20850